Ibrexafungerp to treat acute vulvovaginal candidiasis

Affiliations

Comment

Maria Chiara Masone. Nat Rev Urol. 2021 Nov.

. 2021 Nov;18(11):638.

doi: 10.1038/s41585-021-00522-9.

No abstract available

Comment on

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303).
Schwebke JR, Sobel R, Gersten JK, Sussman SA, Lederman SN, Jacobs MA, Chappell BT, Weinstein DL, Moffett AH, Azie NE, Angulo DA, Harriott IA, Borroto-Esoda K, Ghannoum MA, Nyirjesy P, Sobel JD. Schwebke JR, et al. Clin Infect Dis. 2022 Jun 10;74(11):1979-1985. doi: 10.1093/cid/ciab750. Clin Infect Dis. 2022. PMID: 34467969 Free PMC article. Clinical Trial.

1. Schwebke, J. R. et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a phase 3, randomized, controlled superiority trial (VANISH 303). Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab750 (2021) - DOI - PubMed - PMC